Financial Performance - The company's operating revenue for Q3 2023 was ¥990,148,276.93, a decrease of 5.55% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥126,294,775.88, an increase of 16.64% year-on-year[6]. - The basic earnings per share for the quarter was ¥0.28, reflecting a growth of 21.74% compared to the previous year[7]. - The company reported a 10.23% increase in year-to-date revenue, totaling ¥3,209,858,058.38[6]. - Net profit for the third quarter of 2023 was ¥395,585,705.99, a significant increase of 37.9% from ¥286,918,078.94 in the same quarter of 2022[22]. - The net profit for the year-to-date reached ¥390,446,788.08, marking a 33.56% increase compared to the same period last year[6]. - The net profit for the first three quarters of 2023 was ¥318,443,351.42, slightly down from ¥323,213,879.44 in the previous year, reflecting a decrease of 1.4%[32]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥7,070,546,451.07, representing a 3.75% increase from the end of the previous year[7]. - Total assets as of September 30, 2023, amounted to ¥7,070,546,451.07, an increase from ¥6,815,073,080.14 at the end of 2022[17]. - Current assets totaled ¥4,696,099,211.26, slightly down from ¥4,744,959,783.92 at the end of 2022[17]. - Total liabilities stood at ¥1,462,989,154.78, marginally up from ¥1,459,249,793.23[19]. - The total liabilities decreased to 1,369,129,415.91 RMB from 1,422,243,631.70 RMB year-over-year[30]. - Shareholders' equity rose to ¥5,607,557,296.29 from ¥5,355,823,286.91, reflecting a growth of 4.68%[19]. - The company’s total equity increased to 5,083,259,414.92 RMB from 4,914,468,621.72 RMB, showing a growth of approximately 3.4%[30]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥371,165,786.86, showing a significant increase of 59.28%[7]. - Cash flow from operating activities for the first three quarters of 2023 was ¥371,165,786.86, up from ¥233,023,377.85 in the same period of 2022, indicating a growth of 59.5%[25]. - Total cash inflow from operating activities for the first three quarters of 2023 was ¥2,903,202,784.90, compared to ¥2,549,971,005.34 in 2022, showing an increase of 13.8%[25]. - The cash flow from financing activities resulted in a net outflow of ¥97,742,763.39, an improvement from a net outflow of ¥139,147,323.33 in the same period of 2022[35]. Inventory and Costs - The company experienced a 42.68% increase in inventory during the reporting period[11]. - Inventory increased significantly to ¥828,137,455.67 from ¥580,433,883.92, indicating a 42.7% rise[17]. - Total operating costs for the first three quarters of 2023 were ¥2,802,582,394.58, up from ¥2,610,833,807.86 in 2022, reflecting a growth of 7.3%[21]. - The company's total operating costs increased to ¥1,318,574,872.59, up from ¥1,193,319,253.01 in the same period of 2022, reflecting a rise of 10.5%[31]. Research and Development - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the report[16]. - Research and development expenses for the third quarter of 2023 amounted to ¥255,417,050.30, an increase of 5.5% from ¥241,875,967.94 in the same quarter of 2022[22]. - Research and development expenses for the first three quarters of 2023 were ¥225,289,116.56, slightly up from ¥219,654,878.53 in the previous year, indicating a focus on innovation[31]. Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[36].
辰欣药业(603367) - 2023 Q3 - 季度财报